Receptos to Deliver Scientific Presentations About RPC1063 at the 29th Congress of the European Committee for Treatment and R...
02 October 2013 - 4:00PM
Receptos Inc. (Nasdaq:RCPT) today announced that Company personnel
will deliver two scientific poster presentations about RPC1063 at
the annual meeting of the Congress of the European Committee for
Treatment and Research in Multiple Sclerosis (ECTRIMS) in
Copenhagen, Denmark during October 2-5, 2013. RPC1063 is the
Company's lead sphingosine 1-phosphate 1 receptor (S1P1R) modulator
in Phase 2 development for both relapsing multiple sclerosis (RMS)
and inflammatory bowel disease (IBD).
The first Receptos poster presentation is titled "Results of a
thorough QT/QTc (TQT) study of orally administered RPC1063, a
novel, selective S1P1 receptor (S1P1R) agonist, in healthy adult
volunteers." The data presented in the poster demonstrate that at
steady state, therapeutic and supratherapeutic doses of RPC1063 had
no adverse effect on cardiac repolarization as measured by the
effects on Fridericia corrected QT interval (QTcF), ruling out a
relevant effect of RPC1063 on QT interval. The dose titration
regimen employed during the study appeared to attenuate first dose
heart rate effects and was well tolerated throughout the titration
period. No notable safety issues were identified.
The second Receptos poster presentation is titled "RPC1063, a
potent and selective S1P1R modulator, has a favorable preclinical
safety profile." The data presented in the poster demonstrate an
encouraging preclinical safety profile for RPC1063, in which
RPC1063 was well tolerated in animal toxicology studies up to 9
months in duration, with a wide margin of safety relative to
estimated human therapeutic exposures. In addition, the absence of
fibrotic changes is consistent with the selectivity of RPC1063
towards the S1P1R.
"We continue to build upon our clinical and preclinical
experience with RPC1063 in RMS," said Faheem Hasnain, President and
Chief Executive Officer of Receptos. "In particular, the lack of
effect of RPC1063 on QT prolongation and the modest impact on heart
rate appears to demonstrate a favorable cardiac safety
profile."
Thursday, October 03 at 15:45 Poster Session 1 -
Experimental models Poster 375:
"RPC1063, a potent and selective sphingosine 1-phosphate 1
receptor modulator, has a favourable preclinical safety profile"
Friday, October 04 at 15:30 Poster Session 2 -
Immunomodulation/Immunosuppression Poster 983: "Results of
a thorough QT/QTc (TQT) study of orally administered RPC1063, a
novel, selective S1P1 receptor agonist, in healthy adult
volunteers"
About RPC1063 and S1P1R Modulators
RPC1063 is a novel, oral, once daily, selective and potent S1P1R
modulator in development for autoimmune indications. Previously
reported Phase 1 results demonstrated adequate pharmacokinetic,
pharmacodynamic and safety features, which provide supportive data
for the differentiation strategy for RPC1063 as a potential
best-in-class second generation S1P1R modulator. Receptos is on
track for enrollment completion in Q4 2013 in the randomized Phase
2 portion of a Phase 2/3 study called RADIANCE examining the
efficacy, safety and tolerability of RPC1063 in RMS and is
enrolling a randomized Phase 2 study called TOUCHSTONE examining
the efficacy, safety and tolerability of RPC1063 in ulcerative
colitis (UC). Top-line results for both studies are expected in
mid-2014.
About Receptos
Receptos is a biopharmaceutical company developing therapeutic
candidates for the treatment of immune and metabolic diseases. The
Company's lead program, RPC1063, is an S1P1R small molecule
modulator candidate for immune indications, including RMS and IBD.
The Company is also developing RPC4046, an anti-interleukin-13
(IL-13) antibody for an allergic/immune-mediated Orphan Disease,
eosinophilic esophagitis (EoE). Receptos has established expertise
in high resolution protein crystal structure determination, biology
and drug discovery for G-protein-coupled receptors (GPCRs).
Forward-Looking Statements
Statements contained in this release, other than statements of
historical fact, constitute "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
The words "expects," "believes," "may," "intends," "potential" and
similar expressions are intended to identify forward-looking
statements. These forward-looking statements do not constitute
guarantees of future performance. Investors are cautioned that
forward-looking statements, including without limitation statements
regarding the safety, efficacy and projected development timeline
of drug candidates such as RPC1063 as well as statements regarding
the scope and strength of intellectual property protection,
constitute forward-looking statements. Such forward-looking
statements are subject to a number of risks and uncertainties that
could cause actual results to differ materially from those
anticipated. These forward-looking statements are based upon the
Company's current expectations and involve assumptions that may
never materialize or may prove to be incorrect. Actual results and
the timing of events could differ materially from those anticipated
in such forward-looking statements as a result of various risks and
uncertainties, which include without limitation risks associated
with the process of discovering, developing and commercializing
drug candidates that are safe and effective for use as human
therapeutics. These and other risks are described in detail in the
Company's SEC filings, including the Company's Quarterly Reports on
Form 10-Q and the Company's Registration Statement on Form S-1
which was declared effective on May 8, 2013. All forward-looking
statements contained in this release speak only as of the date on
which they were first made by the Company, and the Company
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after such date.
CONTACT: Media and Investor Contacts:
Graham K. Cooper
Chief Financial Officer, Receptos
(858) 652-5708
gcooper@receptos.com
RECEPTOS, INC. (NASDAQ:RCPT)
Historical Stock Chart
From Jun 2024 to Jul 2024
RECEPTOS, INC. (NASDAQ:RCPT)
Historical Stock Chart
From Jul 2023 to Jul 2024